Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Sep 13

PMID 11553815

Citations 4571

Authors

T Sorlie

C M Perou

R Tibshirani

T Aas

S Geisler

H Johnsen

T Hastie

M B Eisen

M van de Rijn

S S Jeffrey

T Thorsen

H Quist

J C Matese

P O Brown

D Botstein

P E Lonning

A L Borresen-Dale

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

Citing Articles

Improving patient clustering by incorporating structured variable label relationships in similarity measures.

Lambert J, Leutenegger A, Baudot A, Jannot A BMC Med Res Methodol. 2025; 25(1):72.

PMID: 40089699 DOI: 10.1186/s12874-025-02459-8.

Exercise boost after surgery improves survival in model of metastatic breast cancer.

Stagaard R, Jensen A, Schauer T, Bay M, Tavanez A, Wielsoe S Front Immunol. 2025; 16:1533798.

PMID: 40066446 PMC: 11891249. DOI: 10.3389/fimmu.2025.1533798.

Molecular Subtypes of Breast Cancer in Arab Women: Distribution and Prognostic Insights.

Elkum N, Aboussekhra A, Aboussekhra M, Aldalham H, Alshehri L, Alessy S J Epidemiol Glob Health. 2025; 15(1):36.

PMID: 40063309 PMC: 11893967. DOI: 10.1007/s44197-025-00376-z.

Breast cancer prediction based on gene expression data using interpretable machine learning techniques.

Kallah-Dagadu G, Mohammed M, Nasejje J, Mchunu N, Twabi H, Batidzirai J Sci Rep. 2025; 15(1):7594.

PMID: 40038307 PMC: 11880515. DOI: 10.1038/s41598-025-85323-5.

TCGEx: a powerful visual interface for exploring and analyzing cancer gene expression data.

Kus M, Sahin C, Kilic E, Askin A, Ozgur M, Karahanogullari G EMBO Rep. 2025; .

PMID: 40033050 DOI: 10.1038/s44319-025-00407-7.

References

Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R . Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001; 344(8):539-48. DOI: 10.1056/NEJM200102223440801. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Tusher V, Tibshirani R, Chu G . Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98(9):5116-21. PMC: 33173. DOI: 10.1073/pnas.091062498. View

HOWAT J, Barnes D, Harris M, Swindell R . The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease. Br J Cancer. 1983; 47(5):629-40. PMC: 2011376. DOI: 10.1038/bjc.1983.101. View

Barrelet L, Wong Y, LEMARCHAND-BERAUD T, Gomez F . The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer. 1986; 57(6):1171-80. DOI: 10.1002/1097-0142(19860315)57:6<1171::aid-cncr2820570618>3.0.co;2-x. View

Battaglia F, Scambia G, Rossi S, Panici P, Bellantone R, Polizzi G . Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol. 1988; 24(11):1685-90. DOI: 10.1016/0277-5379(88)90068-5. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

Fisher E, Costantino J, Fisher B, Redmond C . Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer. 1993; 71(6 Suppl):2141-50. DOI: 10.1002/1097-0142(19930315)71:6+<2141::aid-cncr2820711603>3.0.co;2-f. View

10.

Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L . Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995; 1(10):1029-34. DOI: 10.1038/nm1095-1029. View

11.

Borresen A, Andersen T, Eyfjord J, Cornelis R, Thorlacius S, Borg A . TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer. 1995; 14(1):71-5. DOI: 10.1002/gcc.2870140113. View

12.

Aas T, Borresen A, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug J . Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996; 2(7):811-4. DOI: 10.1038/nm0796-811. View

13.

Nakopoulou L, Alexiadou A, Theodoropoulos G, Lazaris A, Tzonou A, Keramopoulos A . Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol. 1996; 179(1):31-8. DOI: 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O. View

14.

Torregrosa D, Bolufer P, Lluch A, Lopez J, Barragan E, Ruiz A . Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta. 1997; 262(1-2):99-119. DOI: 10.1016/s0009-8981(97)06542-x. View

15.

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

16.

Foekens J, Look M, Bolt-de Vries J, Meijer-van Gelder M, van Putten W, Klijn J . Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer. 1999; 79(2):300-7. PMC: 2362199. DOI: 10.1038/sj.bjc.6690048. View

17.

Golub T, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J . Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286(5439):531-7. DOI: 10.1126/science.286.5439.531. View

18.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

19.

Berns E, Foekens J, Vossen R, Look M, Devilee P, Henzen-Logmans S . Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000; 60(8):2155-62. View

20.

Geisler S, Lonning P, Aas T, Johnsen H, Fluge O, Haugen D . Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001; 61(6):2505-12. View